ANIK Stock Overview
A joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ANIK from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Anika Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.19 |
| 52 Week High | US$29.12 |
| 52 Week Low | US$11.11 |
| Beta | 0.76 |
| 1 Month Change | -13.05% |
| 3 Month Change | -31.75% |
| 1 Year Change | -52.01% |
| 3 Year Change | -41.90% |
| 5 Year Change | -63.47% |
| Change since IPO | 248.29% |
Recent News & Updates
Recent updates
Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price
May 10
Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet
Dec 19Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?
Jan 30Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth
Aug 03Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity
Mar 11Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?
Jun 25How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?
Mar 16Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly
Feb 09An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued
Jan 13If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%
Dec 18
Shareholder Returns
| ANIK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.7% | 3.7% | 5.3% |
| 1Y | -52.0% | -14.5% | 11.9% |
Return vs Industry: ANIK underperformed the US Biotechs industry which returned -14.5% over the past year.
Return vs Market: ANIK underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| ANIK volatility | |
|---|---|
| ANIK Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ANIK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANIK's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 288 | Cheryl Blanchard | www.anika.com |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief.
Anika Therapeutics, Inc. Fundamentals Summary
| ANIK fundamental statistics | |
|---|---|
| Market cap | US$174.82m |
| Earnings (TTM) | -US$10.83m |
| Revenue (TTM) | US$117.05m |
1.5x
P/S Ratio-16.1x
P/E RatioIs ANIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANIK income statement (TTM) | |
|---|---|
| Revenue | US$117.05m |
| Cost of Revenue | US$44.74m |
| Gross Profit | US$72.31m |
| Other Expenses | US$83.14m |
| Earnings | -US$10.83m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 61.78% |
| Net Profit Margin | -9.25% |
| Debt/Equity Ratio | 0% |
How did ANIK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 10:49 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anika Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Mark Landy | Northland Capital Markets |